Remove Pharmaceutical Remove Safety Remove Therapy
article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., And the Skin Disease of the Year Is….

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor-blinded, head-to-head, multi-center study evaluating upadacitinib vs. dupilumab in adolescents and adults with moderate-to-severe AD who had an inadequate response to systemic therapy or when the use of those therapies was inadvisable.

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. Launches in further European countries are scheduled over the coming months, following national price approvals, via a fully European supply chain.

article thumbnail

Topline Results: Verrica’s VP-315 Performs Well in BCC Trial

The Dermatology Digest

Verrica Pharmaceuticals Inc.’s The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma.

Safety 36
article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement. Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. Click here to buy Theracurmin HP by Integrative Therapeutics (Amazon) 3.

Therapy 69